Novo Nordisk Gains New Drug Approvals, Potentially Boosting 2026 Financials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 03 2026
0mins
Should l Buy NVO?
Source: Yahoo Finance
- New Drug Approvals: Novo Nordisk's weight management drug Wegovy has received approval for metabolic dysfunction-associated steatohepatitis (MASH), which is expected to drive sales exceeding $1 billion, although it may not peak in 2026, it will still positively impact the company.
- Oral Drug Innovation: The oral version of Wegovy becomes the first oral medication approved for weight loss, catering to market demand for daily pills, which could enhance the company's revenue growth.
- Pipeline Progress: Novo Nordisk is advancing a new drug called amycretin, designed to mimic the actions of GLP-1 and amylin, with interim data expected next year, potentially positively influencing market share.
- Market Competition: Despite facing competition from Eli Lilly, Novo Nordisk is poised to regain its share in the GLP-1 market through new drug approvals and pipeline candidates, showcasing potential for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 38.830
Low
42.00
Averages
54.67
High
70.00
Current: 38.830
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Holdings Sees Asset Value Plummet Amid Novo Nordisk Decline
- Asset Management Decline: Novo Holdings reported a significant drop in assets under management from DKK 1,060B (€142B) in 2024 to DKK 694B (€93B) in 2025, reflecting a nearly one-third decrease primarily due to the sharp decline in Novo Nordisk's stock price.
- Impact of Buyback Suspension: The decision by Novo Nordisk to halt share buybacks, coupled with the weakening of the U.S. dollar against the Danish krone, further pressured returns, resulting in a drop in investment returns to about 9% in 2025 from nearly 15% in 2024.
- Portfolio Diversification: Novo Holdings increased its exposure to non-health investments to 48% of its portfolio in 2025, up from 41% in 2024, indicating a strategic shift towards diversification to mitigate market volatility.
- Sales Slowdown Challenges: Novo Nordisk is experiencing a sales slowdown, with its stock dropping approximately 48% in 2025 and another ~24% in 2026, primarily due to intensified competition and cheaper copycat treatments, raising concerns about future growth prospects.
See More
Novo Nordisk Partners with Hims & Hers to Boost Sales
- Market Competition Pressure: Novo Nordisk is losing market share to Eli Lilly in the weight-loss drug sector, which has negatively impacted its sales, although its GLP-1 products still hold significant market potential.
- Strategic Partnership Agreement: The agreement with Hims & Hers allows Novo Nordisk to sell FDA-approved drugs at the same self-pay prices on the platform, which is expected to reduce the appeal of non-FDA-approved versions and boost sales volume.
- Patent Lawsuit Shift: By partnering with Hims & Hers, Novo Nordisk avoids potentially high patent litigation costs while redirecting demand towards its branded medications, thereby enhancing its competitive position in the market.
- Future Product Outlook: Despite a projected revenue decline this year, Novo Nordisk's next-gen GLP-1 drug CagriSema is expected to gain approval within 10 months, with a promising pipeline that could lead to revenue growth over the next three years.
See More
IEA Releases Emergency Oil Reserves Amid Supply Shock
- Emergency Oil Release: The IEA member countries are releasing 400 million barrels of oil in response to the Strait of Hormuz supply shock, with the U.S. contributing 172 million barrels, which may increase household expenses as oil prices rally again.
- Market Reaction: Stock futures are lower this morning due to rising oil prices, reflecting market concerns about the ongoing Iran conflict, and until there is evidence of resolution, the risk of elevated oil prices remains.
- Layoffs and Investment: Atlassian announced a 10% workforce reduction, equating to about 1,600 employees, with the CEO stating this will help self-fund further investments in AI and enterprise sales, highlighting challenges in the traditional software model.
- Private Fund Restrictions: Morgan Stanley and Cliffwater have restricted withdrawals on private credit funds, with Morgan Stanley fulfilling less than half of an 11% redemption request on an $8 billion fund, indicating liquidity issues in the private credit market.
See More
Hims & Hers Partners with Novo Nordisk, Boosting Stock Sentiment
- Partnership Formation: Hims & Hers has established a new partnership with Novo Nordisk to introduce branded GLP-1 treatments like Ozempic and Wegovy, which alleviates legal concerns and strengthens collaboration with a major pharmaceutical company, likely boosting market confidence.
- Weight Loss Strategy Shift: The company is transitioning its U.S. weight-loss business towards FDA-approved treatments, ceasing active promotion of compounded GLP-1 drugs, allowing existing patients to switch to branded therapies when clinically appropriate, aiming to enhance treatment efficacy and patient satisfaction.
- Short Interest Pressure: Short interest in Hims has risen from 81.01 million to 84.96 million shares, with 46.09% of the public float currently held short; given the average daily volume of 32.93 million shares, it would take 2.58 days for short sellers to cover their positions, indicating market attention on potential price rebounds.
- Technical Analysis Status: Hims is trading 59.9% above its 20-day simple moving average but 16% below its 100-day moving average, indicating a strong short-term bounce that has yet to repair the longer-term trend, with shares down 23.73% over the past 12 months.
See More
Bumble Shares Surge 21% on Strong Q4 Results and Positive Guidance
- Bumble's Strong Earnings: Bumble's fourth-quarter results showed strong adjusted EBITDA and revenue, leading to a 21% surge in shares, indicating robust performance in the competitive dating app market and likely attracting further investor interest.
- Netskope's Weak Guidance: Netskope anticipates an adjusted loss of 6 to 7 cents per share for Q1, worse than the 6 cents expected by analysts, resulting in a 17% drop in shares, reflecting market concerns over its future profitability and potential impact on funding.
- Petco's Positive Outlook: Petco's guidance for Q1 adjusted EBITDA between $92 million and $94 million exceeded analyst expectations, causing shares to rise 12%, highlighting strong demand and growth potential in the pet products and services market.
- Hims & Hers Stock Rise: Hims & Hers shares increased over 5% following Eli Lilly's warning about health risks associated with its weight-loss drug, demonstrating market sensitivity to health product issues and investor confidence in the company's future growth.
See More
Novo Nordisk Launches Oral Weight Loss Drug Wegovy
- Market Expansion: Novo Nordisk's launch of the oral version of Wegovy marks the first approved oral GLP-1 for chronic weight management, which is expected to help the company regain market share, especially under competitive pressures.
- Competitive Edge: Eli Lilly's orforglipron has shown strong results in weight management and lowering A1C levels in type 2 diabetes patients, with regulatory approval anticipated in Q2, and the company is poised to launch it quickly post-approval, further solidifying its market leadership.
- Patient Appeal: Unlike oral Wegovy, which requires fasting, orforglipron does not impose dietary restrictions, potentially attracting more patients hesitant about injectable treatments, thus expanding the potential market.
- Multiple Indications: Orforglipron is not only aimed at weight loss but may also be approved for diabetes treatment, with its strong performance in aiding type 2 diabetes patients suggesting higher adoption rates among physicians and patients, reinforcing Eli Lilly's dominance in the oral weight loss market.
See More
Novo Holdings Sees Asset Value Plummet Amid Novo Nordisk Decline
- Asset Management Decline: Novo Holdings reported a significant drop in assets under management from DKK 1,060B (€142B) in 2024 to DKK 694B (€93B) in 2025, reflecting a nearly one-third decrease primarily due to the sharp decline in Novo Nordisk's stock price.
- Impact of Buyback Suspension: The decision by Novo Nordisk to halt share buybacks, coupled with the weakening of the U.S. dollar against the Danish krone, further pressured returns, resulting in a drop in investment returns to about 9% in 2025 from nearly 15% in 2024.
- Portfolio Diversification: Novo Holdings increased its exposure to non-health investments to 48% of its portfolio in 2025, up from 41% in 2024, indicating a strategic shift towards diversification to mitigate market volatility.
- Sales Slowdown Challenges: Novo Nordisk is experiencing a sales slowdown, with its stock dropping approximately 48% in 2025 and another ~24% in 2026, primarily due to intensified competition and cheaper copycat treatments, raising concerns about future growth prospects.
See More
Novo Nordisk Partners with Hims & Hers to Boost Sales
- Market Competition Pressure: Novo Nordisk is losing market share to Eli Lilly in the weight-loss drug sector, which has negatively impacted its sales, although its GLP-1 products still hold significant market potential.
- Strategic Partnership Agreement: The agreement with Hims & Hers allows Novo Nordisk to sell FDA-approved drugs at the same self-pay prices on the platform, which is expected to reduce the appeal of non-FDA-approved versions and boost sales volume.
- Patent Lawsuit Shift: By partnering with Hims & Hers, Novo Nordisk avoids potentially high patent litigation costs while redirecting demand towards its branded medications, thereby enhancing its competitive position in the market.
- Future Product Outlook: Despite a projected revenue decline this year, Novo Nordisk's next-gen GLP-1 drug CagriSema is expected to gain approval within 10 months, with a promising pipeline that could lead to revenue growth over the next three years.
See More
IEA Releases Emergency Oil Reserves Amid Supply Shock
- Emergency Oil Release: The IEA member countries are releasing 400 million barrels of oil in response to the Strait of Hormuz supply shock, with the U.S. contributing 172 million barrels, which may increase household expenses as oil prices rally again.
- Market Reaction: Stock futures are lower this morning due to rising oil prices, reflecting market concerns about the ongoing Iran conflict, and until there is evidence of resolution, the risk of elevated oil prices remains.
- Layoffs and Investment: Atlassian announced a 10% workforce reduction, equating to about 1,600 employees, with the CEO stating this will help self-fund further investments in AI and enterprise sales, highlighting challenges in the traditional software model.
- Private Fund Restrictions: Morgan Stanley and Cliffwater have restricted withdrawals on private credit funds, with Morgan Stanley fulfilling less than half of an 11% redemption request on an $8 billion fund, indicating liquidity issues in the private credit market.
See More
Hims & Hers Partners with Novo Nordisk, Boosting Stock Sentiment
- Partnership Formation: Hims & Hers has established a new partnership with Novo Nordisk to introduce branded GLP-1 treatments like Ozempic and Wegovy, which alleviates legal concerns and strengthens collaboration with a major pharmaceutical company, likely boosting market confidence.
- Weight Loss Strategy Shift: The company is transitioning its U.S. weight-loss business towards FDA-approved treatments, ceasing active promotion of compounded GLP-1 drugs, allowing existing patients to switch to branded therapies when clinically appropriate, aiming to enhance treatment efficacy and patient satisfaction.
- Short Interest Pressure: Short interest in Hims has risen from 81.01 million to 84.96 million shares, with 46.09% of the public float currently held short; given the average daily volume of 32.93 million shares, it would take 2.58 days for short sellers to cover their positions, indicating market attention on potential price rebounds.
- Technical Analysis Status: Hims is trading 59.9% above its 20-day simple moving average but 16% below its 100-day moving average, indicating a strong short-term bounce that has yet to repair the longer-term trend, with shares down 23.73% over the past 12 months.
See More
Bumble Shares Surge 21% on Strong Q4 Results and Positive Guidance
- Bumble's Strong Earnings: Bumble's fourth-quarter results showed strong adjusted EBITDA and revenue, leading to a 21% surge in shares, indicating robust performance in the competitive dating app market and likely attracting further investor interest.
- Netskope's Weak Guidance: Netskope anticipates an adjusted loss of 6 to 7 cents per share for Q1, worse than the 6 cents expected by analysts, resulting in a 17% drop in shares, reflecting market concerns over its future profitability and potential impact on funding.
- Petco's Positive Outlook: Petco's guidance for Q1 adjusted EBITDA between $92 million and $94 million exceeded analyst expectations, causing shares to rise 12%, highlighting strong demand and growth potential in the pet products and services market.
- Hims & Hers Stock Rise: Hims & Hers shares increased over 5% following Eli Lilly's warning about health risks associated with its weight-loss drug, demonstrating market sensitivity to health product issues and investor confidence in the company's future growth.
See More
Novo Nordisk Launches Oral Weight Loss Drug Wegovy
- Market Expansion: Novo Nordisk's launch of the oral version of Wegovy marks the first approved oral GLP-1 for chronic weight management, which is expected to help the company regain market share, especially under competitive pressures.
- Competitive Edge: Eli Lilly's orforglipron has shown strong results in weight management and lowering A1C levels in type 2 diabetes patients, with regulatory approval anticipated in Q2, and the company is poised to launch it quickly post-approval, further solidifying its market leadership.
- Patient Appeal: Unlike oral Wegovy, which requires fasting, orforglipron does not impose dietary restrictions, potentially attracting more patients hesitant about injectable treatments, thus expanding the potential market.
- Multiple Indications: Orforglipron is not only aimed at weight loss but may also be approved for diabetes treatment, with its strong performance in aiding type 2 diabetes patients suggesting higher adoption rates among physicians and patients, reinforcing Eli Lilly's dominance in the oral weight loss market.
See More
